Cara Therapeutics

Travere Therapeutics

Vera Therapeutics

Nephros, Inc.

Akebia Therapeutics

ProKidney Corp. Class A

Aurinia Pharmaceuticals

Ardelyx Inc

Cadrenal Therapeutics, Inc.

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.

The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study: Design and methods for a pharmacy-led trial implemented in low-income populations.

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis.

Anti-Inflammatory Effects of Goat Whey Protein in Concanavalin-A Induced Hepatitis.

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.

<article class="bts-verified-summary" data-ticker="CARA">
<p>Cara Therapeutics (CARA) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>CARA has 20 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CARA%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

Cara Therapeutics (CARA) — BioTechSigns Verified Summary

Cara Therapeutics (CARA) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

CARA has 20 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CARA%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11